Leverkusen, 3 November 2026 – Bayer has raised its 2026 earnings outlook following stronger pharmaceutical performance, even as its agricultural business continues to face commercial pressure.
The German healthcare and agriculture group now expects currency-adjusted core earnings of €9.8 billion to €10.3 billion, compared with its previous forecast of €9.6 billion to €10.1 billion.
Its pharmaceutical division reported third-quarter sales of €4.68 billion, approximately 5% above analysts’ expectations. The stronger performance helped support investor confidence, with Bayer shares rising following the announcement on 3 November.
However, the upgraded outlook does not indicate that every part of the group is recovering equally. The results highlight the importance of understanding how individual divisions contribute to overall corporate performance.
Unlock the Full Article
This article is exclusive to The Ledger Asia Subsribers / PAID members.
Already have an account? Log in here

